-
Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancer Mol. Cancer (IF 27.7) Pub Date : 2025-06-03
Jin Su Kim, Chan Hee Park, Eunyoung Kim, Hee Seung Lee, Jinyoung Lee, Jeehoon Kim, Eun Hee Kam, Sanghee Nam, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Sangwoo Kim, Galam Leem, Seungmin BangPancreatic cancer is a highly lethal malignancy with limited treatment response. Despite advancements in treatment, systemic chemotherapy remains the primary therapeutic approach for over 80% of patients, with no established biomarkers to guide drug selection. Traditional two-dimensional (2D) culture models fail to replicate the tumor microenvironment, necessitating the development of more advanced
-
Reprogrammed immuno-metabolic environment of cancer: the driving force of ferroptosis resistance Mol. Cancer (IF 27.7) Pub Date : 2025-06-03
Sramana Bhowmick, Saptak Banerjee, Viji Shridhar, Susmita MondalFerroptosis, the non-apoptotic, iron-dependent form of cell death is an unavoidable outcome and byproduct of cellular metabolism. Reactive oxygen species generation during metabolic activities transcends to Fe2+-induced lipid peroxidation, leading to ferroptosis. Cancer cells being highly metabolic are more prone to ferroptosis. However, their neoplastic nature enables them to bypass ferroptosis and
-
Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery Mol. Cancer (IF 27.7) Pub Date : 2025-06-03
Hussein Sabit, Timothy M. Pawlik, Faisal Radwan, Mohamed Abdel-Hakeem, Shaimaa Abdel-Ghany, Al-Hassan Soliman Wadan, Mokhtar Elzawahri, Ahmed El-Hashash, Borros ArnethCancer treatment has been revolutionized by immunotherapy and nanomedicine, offering innovative strategies to overcome the tumor microenvironment (TME) complexities. However, challenges such as therapeutic resistance, off-target effects, and immune suppression necessitate advanced delivery systems and combination approaches. Recent advancements in nanoparticle-based therapies, biomimetic platforms
-
Current AI technologies in cancer diagnostics and treatment Mol. Cancer (IF 27.7) Pub Date : 2025-06-02
Ashutosh Tiwari, Soumya Mishra, Tsung-Rong KuoCancer continues to be a significant international health issue, which demands the invention of new methods for early detection, precise diagnoses, and personalized treatments. Artificial intelligence (AI) has rapidly become a groundbreaking component in the modern era of oncology, offering sophisticated tools across the range of cancer care. In this review, we performed a systematic survey of the
-
Loss of TACC2 impairs chemokine CCL3 and CCL4 expression and reduces response to anti-PD-1 therapy in soft tissue sarcoma Mol. Cancer (IF 27.7) Pub Date : 2025-05-30
Jing Yang, Xiuxia Lu, Qiyan Cai, Mengmeng Liu, Tianliang Xia, Dongchun Hong, Liyuan Le, Xinke Zhang, Xing ZhangSoft tissue sarcoma (STS) is a rare, heterogeneous malignancy with limited treatment options for metastatic disease. Despite advances in immunotherapy, including PD-1 inhibitors, clinical outcomes remain suboptimal, highlighting the need for novel biomarkers and therapeutic strategies. This study investigated the role of TACC2 in STS, focusing on its impact on the immune microenvironment and immunotherapy
-
Targeting BATF2-RGS2 axis reduces T-cell exhaustion and restores anti-tumor immunity Mol. Cancer (IF 27.7) Pub Date : 2025-05-30
Xuyu Gu, Chanchan Gao, Xiangyu Su, Yaoyao Zhu, Qiyu Fang, Jia Yu, Ziming Wang, Deping Zhao, Wentian ZhangThis study aims to investigate the role of RGS2 in immune regulation in lung cancer (LC) and explore the regulatory relationship between RGS2 and BATF2 in modulating T cell exhaustion and tumor immune evasion. Single-cell transcriptome-based analysis was performed to identify CD8+ T-cell profiles and regulatory factors in six LC patients receiving neoadjuvant PD-1 blockade therapy. Mouse 3LL cells
-
Clinical approaches to overcome PARP inhibitor resistance Mol. Cancer (IF 27.7) Pub Date : 2025-05-30
Yutian Zou, Hanqi Zhang, Pangzhou Chen, Jiayi Tang, Siwei Yang, Christophe Nicot, Ziyun Guan, Xing Li, Hailin TangPARP inhibitors have profoundly changed treatment options for cancers with homologous recombination repair defects, especially those carrying BRCA1/2 mutations. However, the development of resistance to these inhibitors presents a significant clinical challenge as it limits long-term effectiveness. This review provides an overview of the current understanding of resistance mechanisms to PARP inhibitors
-
Nuclear receptors as novel regulators that modulate cancer radiosensitivity and normal tissue radiotoxicity Mol. Cancer (IF 27.7) Pub Date : 2025-05-30
Xiaochen Meng, Xiaoqian Li, Yi Gao, Shuyu ZhangNuclear receptors (NRs) are a superfamily of transcription factors that are involved in various pathophysiological processes. The human genome contains 48 types of nuclear receptors, including steroid hormone receptors (e.g., estrogen receptor [ER] and vitamin D receptor [VDR]), nonsteroid hormone receptors (e.g. peroxisome proliferator-activated receptor [PPAR] and retinoic acid receptor [RAR]), and
-
Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors Mol. Cancer (IF 27.7) Pub Date : 2025-05-30
Yaiza Senent, Vicente Fresquet, Victoria Jiménez, Karmele Valencia, Francisco Exposito, Patxi San Martín-Úriz, Gracián Camps, Eva Fernández-Pierola, Borja Ruiz-Fernández de Córdoba, Marisol González-Huarriz, Ibon Tamayo, Ana Remírez, Haritz Moreno, Diego Serrano, Daniel Ajona, Marta M. Alonso, Fernando Lecanda, Antonio Pineda-Lucena, Felipe Prósper, Miguel F. Sanmamed, Alfonso Calvo, Jose A. Martinez-ClimentEpigenetic modulators in combination with proapoptotic drugs have become the standard of care treatment in hematological malignancies. Conversely, these combinations have failed to demonstrate clinical efficacy in solid tumors. To address this discrepancy, we conducted a comprehensive analysis of the anti-tumor activity of epigenetic inhibitors in combination with BH3 mimetics that block anti-apoptotic
-
Targeting metastasis in paediatric bone sarcomas Mol. Cancer (IF 27.7) Pub Date : 2025-05-29
Emma C. Bull, Archana Singh, Amy M. Harden, Kirsty Soanes, Hala Habash, Lisa Toracchio, Marianna Carrabotta, Christina Schreck, Karan M. Shah, Paulina Velasco Riestra, Margaux Chantoiseau, Maria Eugénia Marques Da Costa, Gaël Moquin-Beaudry, Pan Pantziarka, Edidiong Akanimo Essiet, Craig Gerrand, Alison Gartland, Linda Bojmar, Anna Fahlgren, Antonin Marchais, Evgenia Papakonstantinou, Eleni M. TomazouPaediatric bone sarcomas (e.g. Ewing sarcoma, osteosarcoma) comprise significant biological and clinical heterogeneity. This extreme heterogeneity affects response to systemic therapy, facilitates inherent and acquired drug resistance and possibly underpins the origins of metastatic disease, a key component implicit in cancer related death. Across all cancers, metastatic models have offered competing
-
NAP1L1 degradation by FBXW7 reduces the deubiquitination of HDGF-p62 signaling to stimulate autophagy and induce primary cisplatin chemosensitivity in nasopharyngeal carcinoma Mol. Cancer (IF 27.7) Pub Date : 2025-05-26
Bin Gong, Yahui Liu, Weiwei Yan, Chao Cheng, Huiling Yang, Jiyu Huang, Qing Liu, Yuyan Liu, Jiankang Guo, Xiaojie Deng, Beixian Zhou, Dayong Zheng, Xiong Liu, Zhen Liu, Weiyi FangNucleosome assembly protein 1-like 1 (NAP1L1) has been implicated in promoting tumor cell proliferation. However, its role in regulating autophagy in tumors, including nasopharyngeal carcinoma (NPC), remains unclear. In this study, we observed that autophagy-inducing agents reduced NAP1L1 protein levels without affecting its mRNA expression. Reduced NAP1L1 enhanced autophagosome formation and maturation
-
GP73-dependent regulation of exosome biogenesis promotes colorectal cancer liver metastasis Mol. Cancer (IF 27.7) Pub Date : 2025-05-26
Linfei Huang, Meng Wei, Huilong Li, Mingxin Yu, Luming Wan, Ruzhou Zhao, Qi Gao, Lijuan Sun, Xufeng Hou, Yunhai Mo, Qing Huang, Lan Zhen, Xiaopan Yang, Jingfei Li, Nan Wang, Chundong Zhang, Haoran Jin, Li Zhou, Yixin Xu, Haotian Lin, Xuhui Zhang, Boan Li, Yue Han, Jing Yuan, Rui Zhang, Feixiang Wu, Hui Zhong, Congwen WeiColorectal cancer (CRC) liver metastasis is the main cause of cancer-related mortality. How liver influences intercellular communication to support CRC liver metastasis remains unknown. Herein, we link GP73, whose chronic upregulation in hepatocytes triggers non-obese metabolic-dysfunction associated steatotic liver disease (MASLD) in mice, with exosome biogenesis and CRC liver metastasis. Mice with
-
Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment Mol. Cancer (IF 27.7) Pub Date : 2025-05-24
Shujie Liu, Anfeng Jiang, Faqing Tang, Minghao Duan, Bin LiCancer remains a significant global health burden due to its high morbidity and mortality. Oncogene-targeted therapy and immunotherapy have markedly improved the 5-year survival rate in the patients with advanced or metastatic tumors compared to outcomes in the era of chemotherapy/radiation. Nevertheless, the majority of patients remain incurable. Initial therapies eliminate the bulk of tumor cells
-
LMTK3 regulation of EV biogenesis and cargo sorting promotes tumour growth by reducing monocyte infiltration and driving pro-tumourigenic macrophage polarisation in breast cancer Mol. Cancer (IF 27.7) Pub Date : 2025-05-23
Mark Samuels, Christos Karakostas, Simoni Besta, Andrea Lauer Betrán, Katerina Tsilingiri, Charlotte Turner, Reza Shirazi Nia, Niloufar Poudine, Richard Goodyear, William Jones, Apostolos Klinakis, Georgios GiamasLemur Tail Kinase 3 (LMTK3) promotes cell proliferation, invasiveness and therapy resistance, and its expression correlates with poor survival in several different malignancies, including breast cancer. Crosstalk through extracellular vesicles (EVs) is an increasingly appreciated mechanism of cell communication within the tumour immune microenvironment, which contributes to different aspects of cancer
-
Biofilm formation by the host microbiota: a protective shield against immunity and its implication in cancer Mol. Cancer (IF 27.7) Pub Date : 2025-05-21
Elena Montanari, Giancarla Bernardo, Valentino Le Noci, Martina Anselmi, Serenella M. Pupa, Elda Tagliabue, Michele Sommariva, Lucia SfondriniHuman-resident microbes typically cluster into biofilms - structurally organized communities embedded within a matrix of self-produced extracellular polymeric substance (EPS) that serves as a protective shield. These biofilms enhance microbial survival and functional adaptability, favoring a symbiotic relationship with the host under physiological conditions. However, biofilms exhibit a dual role in
-
Double-sided niche regulation in skin stem cell and cancer: mechanisms and clinical applications Mol. Cancer (IF 27.7) Pub Date : 2025-05-21
Trang Thao Quoc Pham, Yung-Che Kuo, Wei-Ling Chang, Hao-Jui Weng, Yen-Hua HuangThe niche microenvironment plays a crucial role in regulating the fate of normal skin stem cells (SSCs) and cancer stem cells (CSCs). Therapeutically targeting the CSC niche holds promise as an effective strategy; however, the dual effects of shared SSC niche signaling in CSCs have contributed to the aggressive characteristics of tumors and poor survival rates in skin cancer patients. The lack of a
-
Correction: CircDIDO1 inhibits gastric cancer progression by encoding a novel DIDO1‑529aa protein and regulating PRDX2 protein stability Mol. Cancer (IF 27.7) Pub Date : 2025-05-21
Yu Zhang, Jiajia Jiang, Jiayin Zhang, Han Shen, Maoye Wang, Zhen Guo, Xueyan Zang, Hui Shi, Jiayan Gao, Hui Cai, Xinjian Fang, Hui Qian, Wenrong Xu, Xu ZhangCorrection: Mol Cancer 20, 101 (2021) https://doi.org/10.1186/s12943-021-01390-y Following the publication of the original article [1], the authors have identified two layout-related errors that occurred during the figure assembly or production process. In Figure 2d, the images for the MGC-803 cell invasion assay were inadvertently misplaced. In Additional file 1: Supplementary Figure 1e, the MGC-803
-
SLAMF receptors: key regulators of tumor progression and emerging targets for cancer immunotherapy Mol. Cancer (IF 27.7) Pub Date : 2025-05-17
Jia Li, Tao Fan, Di Wang, Chu Xiao, Ziqin Deng, Wenpeng Cai, Yu Ji, Chunxiang Li, Jie HeThe signaling lymphocytic activation molecule family (SLAMF) consists of nine distinct cell surface receptors predominantly expressed on immune cells, each characterized by unique structural features, expression patterns, downstream signaling pathways, and biological functions. These receptors play critical roles in modulating various immune cell activities within the tumor microenvironment, thereby
-
Death-ision: the link between cellular resilience and cancer resistance to treatments Mol. Cancer (IF 27.7) Pub Date : 2025-05-15
Gustavo Baldassarre, Ivana L. de la Serna, François M. ValletteOne of the key challenges in defeating advanced tumors is the ability of cancer cells to evade the selective pressure imposed by chemotherapy, targeted therapies, immunotherapy and cellular therapies. Both genetic and epigenetic alterations contribute to the development of resistance, allowing cancer cells to survive initially effective treatments. In this narration, we explore how genetic and epigenetic
-
Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring Mol. Cancer (IF 27.7) Pub Date : 2025-05-15
Heng Jiao, Siyun Lin, Jianmin Gu, Dongxian Jiang, Peng Cui, Zhiliang Huang, Yong Fang, Hao Wang, Miao Lin, Han Tang, Tian Jiang, Guangyi Lin, Shaoyuan Zhang, Hao Yin, Fei Liang, Jingshu Wang, Xuning Fan, Fujun Qiu, Yang Yang, Zhigang Li, Bin Li, Jiaqing Xiang, Xuefeng Leng, Yongtao Han, Chengcheng Li, Luoyan Ai, Yingyong Hou, Guoqiang Wang, Zhihong Zhang, Shangli Cai, Tianshu Liu, Jun Yin, Lijie TanAlthough neoadjuvant chemotherapy and immunotherapy show promise in treating oesophageal squamous cell carcinoma (OSCC), long-term survival data are limited. This randomized, multicenter phase 2 study evaluated the efficacy of perioperative Nivolumab with chemotherapy, followed by surgery and adjuvant immunotherapy, in patients with locally advanced resectable OSCC, and explored the prognostic role
-
Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis Mol. Cancer (IF 27.7) Pub Date : 2025-05-15
Hao-Xiang Wu, Yu-Kun Chen, Ying-Nan Wang, Jia-Ying Chen, Shu-Jing Xiang, Ying Jin, Zi-Xian Wang, Chun-Yu Huang, Lu-Ping Yang, Ye He, Wen-Long Guan, Long Bai, Yan-Xing Chen, Min Wang, Chao-Ye Wang, Run-Jie Huang, Yue Huang, Jin-Ling Zhang, Zhi-Da Lv, Si-Qi Yang, Rui-Hua Xu, Qi Zhao, Feng WangSmall cell carcinoma of the esophagus (SCCE) is an aggressive and rare neuroendocrine malignancy with poor prognosis. Here, we firstly performed single-cell transcriptional profiling derived from 10 SCCE patients, with normal esophageal mucosa, adjacent non-malignant tissue and tumors from esophageal squamous cell carcinoma (ESCC) as reference. We observed enrichment of activated regulatory T cells
-
Profiling triple-negative breast cancer-specific super-enhancers identifies high-risk mesenchymal development subtype and BETi-Targetable vulnerabilities Mol. Cancer (IF 27.7) Pub Date : 2025-05-13
Qing-shan Chen, Rui-zhao Cai, Yan Wang, Ge-hao Liang, Kai-ming Zhang, Xiao-Yu Yang, Dong Yang, De-Chang Zhao, Xiao-Feng Zhu, Rong Deng, Jun TangSuper-enhancers (SEs) are critical regulators of tumorigenesis and represent promising targets for bromodomain and extra-terminal domain inhibitors (BETi). However, clinical studies across various solid tumors, including triple-negative breast cancer (TNBC), have demonstrated limited BETi efficacy. This study aims to investigate SE heterogeneity in TNBC and its influence on BETi effectiveness, with
-
N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1 Mol. Cancer (IF 27.7) Pub Date : 2025-05-10
Bar Kaufman, Muhammad Abu-Ahmad, Olga Radinsky, Eman Gharra, Tal Manko, Baisali Bhattacharya, Daniela Gologan, Nofar Erlichman, Tsipi Meshel, Yoav Nuta, Tomer Cooks, Moshe Elkabets, Adit Ben-Baruch, Angel PorgadorThe PD-L1/PD-1 pathway is crucial for immune regulation and has become a target in cancer immunotherapy. However, in order to improve patient selection for immune checkpoint blockade (ICB) therapies, better selection criteria are needed. This study explores how the N-glycosylation of PD-L1 affects its interaction with PD-1 and ICB efficacy, focusing on its four N-linked glycosylation sites: N35, N192
-
Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer Mol. Cancer (IF 27.7) Pub Date : 2025-05-09
Soo-Yeon Hwang, Yoojeong Seo, Seojeong Park, Seul-Ah Kim, Inhye Moon, Yi Liu, Seojeong Kim, Eun Seon Pak, Sehyun Jung, Hyeyoon Kim, Kyung-Hwa Jeon, Seung Hee Seo, Inyoung Sung, Heetak Lee, So-Yeon Park, Younghwa Na, Tae Il Kim, Youngjoo KwonColorectal cancer (CRC) is one of the most prevalent cancers worldwide, with KRAS mutations playing a significant role in its tumorigenesis. Among the KRAS variants, the G13D mutation is associated with poor prognosis and distinctive biological behaviors. This study focuses on the role of HER2, a critical prognostic and predictive biomarker, in modulating the unique characteristics of KRASG13D-mutated
-
Protein lipidation in the tumor microenvironment: enzymology, signaling pathways, and therapeutics Mol. Cancer (IF 27.7) Pub Date : 2025-05-07
Mengke Xu, Bo XuProtein lipidation is a pivotal post-translational modification that increases protein hydrophobicity and influences their function, localization, and interaction network. Emerging evidence has shown significant roles of lipidation in the tumor microenvironment (TME). However, a comprehensive review of this topic is lacking. In this review, we present an integrated and in-depth literature review of
-
Correction: SPOP‑mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions Mol. Cancer (IF 27.7) Pub Date : 2025-05-07
Qiwei Jiang, Nana Zheng, Lang Bu, Xiaomei Zhang, Xiaoling Zhang, Yuanzhong Wu, Yaqing Su, Lei Wang, Xiaomin Zhang, Shancheng Ren, Xiangpeng Dai, Depei Wu, Wei Xie, Wenyi Wei, Yasheng Zhu, Jianping GuoCorrection: Mol Cancer 20, 100 (2021) https://doi.org/10.1186/s12943-021-01397-5 Following publication of the original article [1], the authors identified the tubulin band of Figure 2C and 4M was duplicated used. They sincerely apologize for the inadvertent duplication during data arrangement. Here, they provide the original data to clarify that these tubulin bands were run on the same gel. However
-
Advances in cancer immunotherapy: historical perspectives, current developments, and future directions Mol. Cancer (IF 27.7) Pub Date : 2025-05-07
Meiyin Zhang, Chaojun Liu, Jing Tu, Min Tang, Milad Ashrafizadeh, Noushin Nabavi, Gautam Sethi, Peiqing Zhao, Shijian LiuCancer immunotherapy, encompassing both experimental and standard-of-care therapies, has emerged as a promising approach to harnessing the immune system for tumor suppression. Experimental strategies, including novel immunotherapies and preclinical models, are actively being explored, while established treatments, such as immune checkpoint inhibitors (ICIs), are widely implemented in clinical settings
-
A comprehensive overview of ovarian cancer stem cells: correlation with high recurrence rate, underlying mechanisms, and therapeutic opportunities Mol. Cancer (IF 27.7) Pub Date : 2025-05-07
Hadi Alizadeh, Parastoo Akbarabadi, Alireza Dadfar, Mohammad Reza Tareh, Bahram SoltaniOvarian cancer is one of the most lethal gynecological malignancies, with a recurrence rate of 70–80%, particularly in patients diagnosed at advanced stages (stage III or IV), where the five-year survival rate falls below 30%. A key driver of this recurrence is the presence of cancer stem cells (CSCs), which exhibit resistance to chemotherapy and possess the capacity for self-renewal, plasticity, and
-
The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer Mol. Cancer (IF 27.7) Pub Date : 2025-05-05
Emine Atas, Kerstin Berchtold, Michaela Schlederer, Sophie Prodinger, Felix Sternberg, Perla Pucci, Christopher Steel, Jamie D. Matthews, Emily R. James, Cécile Philippe, Karolína Trachtová, Ali A. Moazzami, Nastasiia Artamonova, Felix Melchior, Torben Redmer, Gerald Timelthaler, Elena E. Pohl, Suzanne D. Turner, Isabel Heidegger, Marcus Krueger, Ulrike Resch, Lukas KennerProstate cancer (PCa) and Type 2 diabetes (T2D) often co-occur, yet their relationship remains elusive. While some studies suggest that T2D lowers PCa risk, others report conflicting data. This study investigates the effects of peroxisome proliferator-activated receptor (PPAR) agonists Bezafibrate, Tesaglitazar, and Pioglitazone on PCa tumorigenesis. Analysis of patient datasets revealed that high
-
Cancer-nervous system crosstalk: from biological mechanism to therapeutic opportunities Mol. Cancer (IF 27.7) Pub Date : 2025-05-05
Sirui Huang, Jing Zhu, Linglu Yu, Yan Huang, Yue HuA growing body of research suggests a bidirectional interaction between cancer and the nervous system. Neural cells exert their effects on tumors by secreting neurotransmitters and cell adhesion molecules, which interact with specific receptors on tumor cells to modulate their behavior. Conversely, tumor-secreted factors, particularly including inflammatory factors, can alter neural activity and increase
-
Lymph node macrophage-targeted interferon alpha boosts anticancer immune responses by regulating CD169-positive phenotype of macrophages Mol. Cancer (IF 27.7) Pub Date : 2025-05-03
Ryo Fukuda, Yukio Fujiwara, Hitoshi Maeda, Cheng Pan, Yuki Minayoshi, Hiromu Yano, Yuki Mizuta, Mei Takano, Rin Yamada, Yoichi Saito, Kenshiro Hirata, Shuhei Imoto, Keishi Yamasaki, Kentaro Oniki, Junji Saruwatari, Masaki Otagiri, Hiroshi Watanabe, Yoshihiro Komohara, Toru MaruyamaCD169+ macrophages in lymph nodes (LNs) activate cytotoxic T lymphocytes (CTLs), which play a crucial role in anticancer immunity, through antigen presentation and co-stimulation by CD169. Interferon alpha (IFNα) is capable of inducing the CD169+ phenotype of macrophages; however, its clinical applications have been hindered by pharmacokinetic limitations—low LN distribution and an inability to target
-
Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives Mol. Cancer (IF 27.7) Pub Date : 2025-05-03
Chen Huang, Jiayi Li, Ruiyan Wu, Yangqian Li, Chenliang ZhangPyroptosis is a distinct form of programmed cell death characterized by the rupture of the cell membrane and robust inflammatory responses. Increasing evidence suggests that pyroptosis significantly affects the tumor microenvironment and antitumor immunity by releasing damage-associated molecular patterns (DAMPs) and pro-inflammatory mediators, thereby establishing it as a pivotal target in cancer
-
Does side matter? Deciphering mechanisms that underpin side-dependent pathogenesis and therapy response in colorectal cancer Mol. Cancer (IF 27.7) Pub Date : 2025-05-02
Harrison J. Boka, Rebekah M. Engel, Christine Georges, Paul J. McMurrick, Helen E. AbudColorectal cancer (CRC) is stratified by heterogeneity between disease sites, with proximal right-sided CRC (RCRC) multifactorial in its distinction from distal left-sided CRC (LCRC). Notably, right-sided tumors are associated with aggressive disease characteristics which culminate in poor clinical outcomes for these patients. While factors such as mutational profile and patterns of metastasis have
-
Multi‑omics analysis identifies different molecular subtypes with unique outcomes in early-stage poorly differentiated lung adenocarcinoma Mol. Cancer (IF 27.7) Pub Date : 2025-05-01
Bing Liu, Wei Tao, Xuantong Zhou, Li-Di Xu, Yanrui Luo, Xin Yang, Qingjie Min, Miao Huang, Yuge Zhu, Xinrun Cui, Yaqi Wang, Tongyang Gong, Enli Zhang, Yu S. Huang, Weizhi Chen, Shi Yan, Nan WuEarly-stage poorly differentiated lung adenocarcinoma (LUAD) is plagued by a high risk of postoperative recurrence, and its prognostic heterogeneity complicates treatment and surveillance planning. We conducted this integrative multi-omics study to identify those patients with a truly high risk of adverse outcomes. Whole-exome, RNA and whole methylome sequencing were carried out on 101 treatment-naïve
-
Therapy-induced senescence is a transient drug resistance mechanism in breast cancer Mol. Cancer (IF 27.7) Pub Date : 2025-05-01
Eszter Bajtai, Csaba Kiss, Éva Bakos, Tamás Langó, Anna Lovrics, Éva Schád, Viktória Tisza, Károly Hegedűs, Péter Fürjes, Zoltán Szabó, Gábor E. Tusnády, Gergely Szakács, Ágnes Tantos, Sándor Spisák, József Tóvári, András FürediTherapy-induced senescence (TIS) is considered a permanent cell cycle arrest following DNA-damaging treatments; however, its irreversibility has recently been challenged. Here, we demonstrate that escape from TIS is universal across breast cancer cells. Moreover, TIS provides a reversible drug resistance mechanism that ensures the survival of the population, and could contribute to relapse. TIS was
-
Epigenomic disorder and partial EMT impair luminal progenitor integrity in Brca1-associated breast tumorigenesis Mol. Cancer (IF 27.7) Pub Date : 2025-04-28
Camille Landragin, Melissa Saichi, Marthe Laisné, Adeline Durand, Pacôme Prompsy, Renaud Leclere, Jérémy Mesple, Kyra Borgman, Amandine Trouchet, Marisa M. Faraldo, Aurélie Chiche, Anne Vincent-Salomon, Hélène Salmon, Céline VallotIn breast cancer related to the BRCA1 mutation, luminal progenitor cells are believed to be the cells of origin, yet how these cells transform into invasive cancer cells remain poorly understood. Here, we combine single-cell epigenomic and transcriptomic data to reconstitute sequences of events in luminal cells that lead to tumorigenesis. Upon deletion of Trp53 and Brca1, we find that luminal progenitors
-
Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy Mol. Cancer (IF 27.7) Pub Date : 2025-04-28
Yufei Lu, Fu ZhaoChimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of B cell and plasma cell malignancies, and numerous promising targets against solid tumours are being explored. Despite their initial therapeutic success in hematological cancers, relapse occurs in a significant fraction of patients, highlighting the need for further innovations in advancing CAR T cell therapy. Tumour
-
The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates Mol. Cancer (IF 27.7) Pub Date : 2025-04-26
Liuyue Kan, Ying Yu, Yaxue Wang, Lei Shi, Tingyuan Fan, Hui Chen, Chuanli RenGastric cancer (GC) is a prevalent digestive system tumor, the fifth most diagnosed cancer worldwide, and a leading cause of cancer deaths. GC is distinguished by its pronounced heterogeneity and a dynamically evolving tumor microenvironment (TME). The lack of accurate disease models complicates the understanding of its mechanisms and impedes the discovery of novel drugs. A growing body of evidence
-
Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation Mol. Cancer (IF 27.7) Pub Date : 2025-04-24
Soyeon Yi, Kyunghee Noh, Hyeran Kim, Eunkyeong Jung, Suhyeon Kim, Jieun Lee, Kyeonghye Guk, Jinsol Choi, Eun-Kyung Lim, Seokho Kim, Hwangseo Park, Jung Hwa Lim, Cho-Rok Jung, Taejoon Kang, Juyeon JungPancreatic adenocarcinoma (PAAD) is highly challenging to treat due to its poor prognosis and limited effective treatment options. Liposomal nanotechnology has emerged as a promising drug delivery platform in oncology, but existing liposomal therapies face limitations such as systemic toxicity, insufficient tumor selectivity, and low target specificity. Mesothelin (MSLN), an antigen overexpressed in
-
Emerging artificial intelligence-driven precision therapies in tumor drug resistance: recent advances, opportunities, and challenges Mol. Cancer (IF 27.7) Pub Date : 2025-04-23
Yuan Mao, Dangang Shangguan, Qi Huang, Ling Xiao, Dongsheng Cao, Hui Zhou, Yi-Kun WangDrug resistance is one of the main reasons for cancer treatment failure, leading to a rapid recurrence/disease progression of the cancer. Recently, artificial intelligence (AI) has empowered physicians to use its powerful data processing and pattern recognition capabilities to extract and mine valuable drug resistance information from large amounts of clinical or omics data, to study drug resistance
-
LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancer Mol. Cancer (IF 27.7) Pub Date : 2025-04-23
Christopher A. Ladaika, Averi Chakraborty, Ashiq Masood, Galen Hostetter, Joo Mi Yi, Heather M. O’HaganBRAF activating mutations occur in approximately 10% of metastatic colorectal cancer (CRCs) and are associated with worse prognosis in part due to an inferior response to standard chemotherapy. Standard of care for patients with refractory metastatic BRAFV600E CRC is treatment with BRAF and EGFR inhibitors and recent FDA approval was given to use these inhibitors in combination with chemotherapy for
-
Exploring molecular and cellular mechanisms of Pre-Metastatic niche in renal cell carcinoma Mol. Cancer (IF 27.7) Pub Date : 2025-04-22
Xiao Zhou, Ruirui Li, Maode Lai, Chong LaiRenal cell carcinoma (RCC) is among the most frequently occurring types of cancer, and its metastasis is a major contributor to its elevated mortality. Before the primary tumor metastasizes to secondary or distant organs, it remodels the microenvironment of these sites, creating a pre-metastatic niche (PMN) conducive to the colonization and growth of metastatic tumors. RCC releases a variety of biomolecules
-
Retraction Note: Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells Mol. Cancer (IF 27.7) Pub Date : 2025-04-19
Parthasarathy Chandrakesan, Jiannan Yao, Dongfeng Qu, Randal May, Nathaniel Weygant, Yang Ge, Naushad Ali, Sripathi M. Sureban, Modhi Gude, Kenneth Vega, Eddie Bannerman-Menson, Lijun Xia, Michael Bronze, Guangyu An, Courtney W. HouchenRetraction note:Mol Cancer16, 30 (2017) https://doi.org/10.1186/s12943-017-0594-y The Editor-in-Chief has retracted this article. After publication, concerns were raised regarding highly similar images in some of the figures, specifically: Fig. 3D Bmi1 and Fig. 3F Hes1 blots appear highly similar; Fig. 3D Lgr 5 and Fig. 3F B-catenin blots appear highly similar; Fig. 3D Musashi1 Fig. 3F NFκBp65 blots
-
Transient intracellular expression of PD-L1 and VEGFR2 bispecific nanobody in cancer cells inspires long-term T cell activation and infiltration to combat tumor and inhibit cancer metastasis Mol. Cancer (IF 27.7) Pub Date : 2025-04-19
Lei Zhang, Yunfeng Lin, Li Hu, Yanan Wang, Chaohua Hu, Xinyi Shangguan, Shuzhi Tang, Jincan Chen, Ping Hu, Zhe-Sheng Chen, Zun-Fu Ke, Zhuo ChenPD-L1, an immune checkpoint inhibitor, and VEGFR2, essential for cancer metastasis, play pivotal roles in tumorigenesis. However, their miniature bispecific intracellular nanobodies for combining check-point blockade and anti-metastasis anticancer therapy remain underexplored. The intrabodies were developed using gene cloning technology. Specificity of the intrabodies was testified using Western blot
-
Lung-specific metastasis: the coevolution of tumor cells and lung microenvironment Mol. Cancer (IF 27.7) Pub Date : 2025-04-16
Guixiu Xiao, Xinmin Wang, Zihan Xu, Yanyang Liu, Jing JingThe vast majority of cancer-related deaths are attributed to metastasis. The lung, being a common site for cancer metastasis, is highly prone to being a target for multiple cancer types and causes a heavy disease burden. Accumulating evidence has demonstrated that tumor metastasis necessitates continuous interactions between tumor cells and distant metastatic niches. Nevertheless, a comprehensive elucidation
-
Correction: Targeting SOST using a small‑molecule compound retards breast cancer bone metastasis Mol. Cancer (IF 27.7) Pub Date : 2025-04-16
Lisha Sun, Yixiao Zhang, Guanglei Chen, Yaoting Ji, Qingtian Ma, Xinbo Qiao, Sijin Wu, Lin Zhou, Jiawen Bu, Xudong Zhu, Xiaoying Zhang, Xiaofan Jiang, Chao Liu, Xinnan Li, Yang Liu, Yongliang Yang, Caigang LiuCorrection: Mol Cancer 21, 228 (2022) https://doi.org/10.1186/s12943-022-01697-4 Following publication of the original article [1], the authors dentified an inadvertent image duplication in the supplementary Figure S2-C which occurred during the figure preparation process and wish to formally request an erratum to rectify this issue. The updated Figure S2-C can be downloaded from the link provided
-
ADAR1-high tumor-associated macrophages induce drug resistance and are therapeutic targets in colorectal cancer Mol. Cancer (IF 27.7) Pub Date : 2025-04-16
Hibiki Umeda, Kunitoshi Shigeyasu, Toshiaki Takahashi, Kazuya Moriwake, Yoshitaka Kondo, Kazuhiro Yoshida, Sho Takeda, Shuya Yano, Yuki Matsumi, Hiroyuki Kishimoto, Tomokazu Fuji, Kazuya Yasui, Hideki Yamamoto, Kosei Takagi, Masashi Kayano, Hiroyuki Michiue, Keiichiro Nakamura, Yoshiko Mori, Fuminori Teraishi, Hiroshi Tazawa, Yuzo Umeda, Shunsuke Kagawa, Ajay Goel, Toshiyoshi FujiwaraColorectal cancer (CRC) is considered the third most common type of cancer worldwide. Tumor-associated macrophages (TAMs) have been shown to promote drug resistance. Adenosine-to-inosine RNA-editing, as regulated by adenosine deaminase acting on RNA (ADAR), is a process that induces the posttranscriptional modification of critical oncogenes. The aim of this study is to determine whether the signals
-
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer Mol. Cancer (IF 27.7) Pub Date : 2025-04-14
Fei Xing, Hongli Gao, Guanglei Chen, Lisha Sun, Jiayi Sun, Xinbo Qiao, Jinqi Xue, Caigang LiuCorrection: Mol Cancer 22, 6 (2023) https://doi.org/10.1186/s12943-023–01716-y Following publication of the original article [1], the authors sincerely acknowledge that an incorrect image panel was inadvertently included in Figure 3F and 4H. To ensure the accuracy and integrity of the article, the authors have carefully reviewed the original data and replaced the erroneous images. This correction does
-
KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia Mol. Cancer (IF 27.7) Pub Date : 2025-04-14
Hyun-Jin Kwon, Ji Eun Shin, Amir Khan, So Yeon Park, Jiyoung Kim, Jee-Young Lee, Doohyun Lee, Seungyeon Lee, Chun Young Im, Heegyum Moon, Ye Ri Han, Minori Tamai, Koshi Akahane, Takeshi Inukai, Wonhwa Lee, Hyelim Kim, Hong Nam Kim, Sung-Min Ahn, Hyun Woo Park, Dong-Wook KimBlast phase chronic myeloid leukemia (BP-CML) poses significant clinical challenges due to its drug resistance, resulting from BCR::ABL1-dependent mutations and BCR::ABL1-independent pathways. Previously, we reported that FLT3 pathway is activated in ~ 50% of BP-CML cases, indicating a potential avenue for therapeutic intervention via dual inhibition of BCR::ABL1 and FLT3. Here, we aimed to evaluate
-
BIRC2 blockade facilitates immunotherapy of hepatocellular carcinoma Mol. Cancer (IF 27.7) Pub Date : 2025-04-14
Lingyi Fu, Shuo Li, Jie Mei, Ziteng Li, Xia Yang, Chengyou Zheng, Nai Li, Yansong Lin, Chao Cao, Lixuan Liu, Liyun Huang, Xiujiao Shen, Yuhua Huang, Jingping YunThe effectiveness of immunotherapy in hepatocellular carcinoma (HCC) is limited, however, the molecular mechanism remains unclear. In this study, we identified baculoviral IAP repeat-containing protein 2 (BIRC2) as a key regulator involved in immune evasion of HCC. Genome-wide CRISPR/Cas9 screening was conducted to identify tumor-intrinsic genes pivotal for immune escape. In vitro and in vivo models
-
Editorial expression of concern: Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism Mol. Cancer (IF 27.7) Pub Date : 2025-04-14
Jing-Jing Zhang, Yi Zhu, Kun-Ling Xie, Yun-Peng Peng, Jin-Qiu Tao, Jie Tang, Zheng Li, Ze-Kuan Xu, Cun-Cai Dai, Zhu-Yin Qian, Kui-Rong Jiang, Jun-Li Wu, Wen-Tao Gao, Qing Du, Yi MiaoCorrection: Mol Cancer 13, 130 (2014) https://doi.org/10.1186/1476-4598-13-130 The Editor-in-Chief is issuing an editorial expression of concern to alert readers that after the publication of this article, it was brought to the attention of the publisher that there are a number of image integrity concerns. There appear to be high similarities between Fig. 1e GAPDH and Fig. 3b GAPDH, representing different
-
Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer Mol. Cancer (IF 27.7) Pub Date : 2025-04-09
Xiaolu Cui, Siyuan Liu, He Song, Jingjing Xu, Yanbin SunNon-small cell lung cancer (NSCLC) represents the most common pathological type of lung cancer, and the combination of neoadjuvant immunotherapy with chemotherapy has emerged as the first-line treatment for NSCLC. Nevertheless, the efficacy of this therapeutic approach remains variable. The present study aims to examine the impact of chemoimmunotherapy in NSCLC patients, with a view to identifying
-
Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response Mol. Cancer (IF 27.7) Pub Date : 2025-04-09
Fanhong Zeng, Qingyang Zhang, Yu-Man Tsui, Huanhuan Ma, Lu Tian, Abdullah Husain, Jingyi Lu, Joyce Man-Fong Lee, Vanilla Xin Zhang, Po-Man Li, Gary Cheuk-Hang Cheung, Tan-To Cheung, Daniel Wai-Hung Ho, Irene Oi-Lin NgA striking characteristic of liver cancer is its extensive heterogeneity, particularly with regard to its varied response to immunotherapy. In this study, we employed multimodal sequencing approaches to explore the various aspects of neoadjuvant nivolumab treatment in liver cancer patients. We used spatially-resolved transcriptomics, single- and bulk-cell transcriptomics, and TCR clonotype analyses
-
Caveolin-1: an ambiguous entity in breast cancer Mol. Cancer (IF 27.7) Pub Date : 2025-04-07
Naveen Chintalaramulu, Dhirendra Pratap Singh, Biplov Sapkota, Dayanidhi Raman, Suresh Alahari, Joseph FrancisBreast cancer (BC) is the most frequently diagnosed cancer in women and the second leading cause of death from cancer among women. Metastasis is the major cause of BC-associated mortality. Accumulating evidence implicates Caveolin-1 (Cav-1), a structural protein of plasma membrane caveolae, in BC metastasis. Cav-1 exhibits a dual role, as both a tumor suppressor and promoter depending on the cellular
-
Editorial Expression of Concern: Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: Pathological significance in early- and late-onset breast carcinoma Mol. Cancer (IF 27.7) Pub Date : 2025-04-05
Satyabrata Sinha, Ratnesh K. Singh, Neyaz Alam, Anup Roy, Susanta Roychoudhury, Chinmay Kumar PandaCorrection: Mol Cancer 7, 84 (2008) https://doi.org/10.1186/1476-4598-7-84. The Editor-in-Chief would like to alert the readers that concerns have been raised regarding some of the data presented in the figures. Specifically: In Fig. 1c (upper panel), the 588 T and 366 D9S104 bands appear highly similar, and the 4131 T D9S104 band appears highly similar to 3025 N PHF2 ex-18. In Fig. 3b, the two upper
-
Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation Mol. Cancer (IF 27.7) Pub Date : 2025-04-02
Muhammad Tufail, Can-Hua Jiang, Ning LiThe Wnt signaling pathway plays a crucial role in development and tissue homeostasis, regulating key cellular processes such as proliferation, differentiation, and apoptosis. However, its abnormal activation is strongly associated with tumorigenesis, metastasis, and resistance to therapy, making it a vital target for cancer treatment. This review provides a comprehensive insight into the role of Wnt
-
Regulation of cellular senescence in tumor progression and therapeutic targeting: mechanisms and pathways Mol. Cancer (IF 27.7) Pub Date : 2025-04-02
Bowei Liu, Zhigang Peng, Hao Zhang, Nan Zhang, Zaoqu Liu, Zhiwei Xia, Shaorong Huang, Peng Luo, Quan ChengCellular senescence, a stable state of cell cycle arrest induced by various stressors or genomic damage, is recognized as a hallmark of cancer. It exerts a context-dependent dual role in cancer initiation and progression, functioning as a tumor suppressor and promoter. The complexity of senescence in cancer arises from its mechanistic diversity, potential reversibility, and heterogeneity. A key mediator
-
Small open reading frame-encoded microproteins in cancer: identification, biological functions and clinical significance Mol. Cancer (IF 27.7) Pub Date : 2025-04-02
Tingting Zhang, Zhang Li, Jiao Li, Yong PengThe human genome harbors approximately twenty thousand protein-coding genes, and a significant portion of life science research focuses on elucidating their functions and the underlying mechanisms. Recent studies have revealed that small open reading frame (sORF), originating from non-coding RNAs or the 5’ leader sequences of messenger RNAs, can be translated into small peptides called microproteins
-
Retraction Note: Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis Mol. Cancer (IF 27.7) Pub Date : 2025-04-01
Pawan Kumar, Arti Yadav, Samip N. Patel, Mozaffarul Islam, Quintin Pan, Sofia D. Merajver, Theodoros N. TeknosRetraction Note: Mol Cancer 9, 206 (2010) https://doi.org/10.1186/1476-4598-9-206 The Editor-in-Chief has retracted this article. After publication, concerns were raised regarding highly similar images between this article and the authors’ earlier publication [1]. Specifically, Fig. 5A TM- image in this article appears to overlap with Fig. 6C UM-SCC-74 A + EC-Bcl-2 in [1], and Fig. 5A TM + image appears
-
Editorial expression of concern: Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase Mol. Cancer (IF 27.7) Pub Date : 2025-03-31
Susmita Mondal, Chandan Mandal, Rajender Sangwan, Sarmila Chandra, Chitra MandalCorrection: Mol Cancer 9, 239 (2010) https://doi.org/10.1186/1476-4598-9-239 The Editor-in-Chief is issuing this editorial expression of concern to inform the readers that following the publication of the article, concerns were raised regarding multiple image similarities found in Figs. 1B and E and 2C, 3 A, 4 A, 5 A, and 7E. Due to the age of the article, the authors were unable to provide all concerned